This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradshaw, D.
Right arrow Articles by Geretti, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradshaw, D.
Right arrow Articles by Geretti, A. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4489-4491, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00687-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Novel Drug Resistance Pattern Associated with the Mutations K70G and M184V in Human Immunodeficiency Virus Type 1 Reverse Transcriptase{triangledown}

D. Bradshaw,1 S. Malik,2 C. Booth,1 M. Van Houtte,3 T. Pattery,3 A. Waters,4 J. Ainsworth,4 and A. M. Geretti1,2*

Royal Free Hospital,1 Royal Free & University College Medical School, London, United Kingdom,2 Virco BVBA, Mechelen, Belgium,3 Department of HIV Medicine, North Middlesex University Hospital, London, United Kingdom4

Received 24 May 2007/ Returned for modification 25 July 2007/ Accepted 31 August 2007

We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.

* Corresponding author. Mailing address: Department of Virology, Royal Free Hospital, Pond Street, London NW3 2QG, United Kingdom. Phone: 44 (0)20 7794 0500, ext. 36295. Fax: 44 (0)20 7830 2854. E-mail: a.geretti{at}medsch.ucl.ac.uk

{triangledown} Published ahead of print on 17 September 2007.

Antimicrobial Agents and Chemotherapy, December 2007, p. 4489-4491, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00687-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shahriar, R., Rhee, S.-Y., Liu, T. F., Fessel, W. J., Scarsella, A., Towner, W., Holmes, S. P., Zolopa, A. R., Shafer, R. W. (2009). Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations. Antimicrob. Agents Chemother. 53: 4869-4878 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»